Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04637594

Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy (IMAGINE)

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Locally Advanced Bladder Urothelial Carcinoma Locally Advanced Renal Pelvis Urothelial Carcinoma Locally Advanced Ureter Urothelial Carcinoma Locally Advanced Urethral Urothelial Carcinoma Locally Advanced Urothelial Carcinoma Metastatic Bladder Urothelial Carcinoma Metastatic Renal Pelvis Urothelial Carcinoma Metastatic Ureter Urothelial Carcinoma Metastatic Urethral Urothelial Carcinoma Metastatic Urothelial Carcinoma

Interventions Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab

Updated 22 times since 2020 Last updated: Jan 13, 2025 Started: May 27, 2022 Primary completion: Jun 1, 2024 Completion: Sep 30, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04637594, this PHASE3 trial focuses on Locally Advanced Bladder Urothelial Carcinoma and Locally Advanced Renal Pelvis Urothelial Carcinoma and remains ongoing. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 22 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

22 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 17 earlier versions

Oct 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Apr 2023 — Sep 2023 [monthly]

Recruiting PHASE3
May 2022 — Apr 2023 [monthly]

Recruiting PHASE3
Apr 2022 — May 2022 [monthly]

Recruiting PHASE3
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE3
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE3
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE3
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE3
Sep 2021 — Nov 2021 [monthly]

Recruiting PHASE3
May 2021 — Sep 2021 [monthly]

Recruiting PHASE3
Apr 2021 — May 2021 [monthly]

Recruiting PHASE3
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE3
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Adrian, United States , Albuquerque, United States , Allentown, United States , Alton, United States , Ames, United States , Anchorage, United States , Ann Arbor, United States , Antioch, United States , Arroyo Grande, United States and 243 more locations